Asia-Pacific

Oncology

oncological practices today, with ESMO branding

5 clinical advances and related implications from ESMO 2025

5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.

Oncology

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

News

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medic

News

GlobalHealthPR Spurwing_Communications Emma Thompson

GLOBALHealthPR adds Spurwing Communications to its network

GLOBALHealthPR has boosted its Asia-Pacific reach with the addition of Spurwing Communications to its independent med comms network.

News

AZ tried to buy Daiichi Sankyo last year - report

Trading in shares of Daiichi Sankyo was suspended yesterday.

Views & Analysis

Regulatory timelines in the Asia-Pacific

Snapshot of clinical trial application processes in the region.

5 clinical advances and related implications from ESMO 2025

ESMO 2025 commences: ADCs, AI, and Asia

On heels of new data, Gilead pays $455m for Asian Trodelvy r...

GLOBALHealthPR adds Spurwing Communications to its network

AZ tried to buy Daiichi Sankyo last year - report

Regulatory timelines in the Asia-Pacific

Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ...

Discover a new era of healthcare panel engagement: Grounded ...

Asia-Pacific

Editor's Picks